New Rice-Derived Short Peptide Potently Alleviated Hyperuricemia Induced by Potassium Oxonate in Rats

Abstract

Gout that caused by hyperuricemia affects human health seriously and more efficient drugs are urgently required clinically. In this study, a novel peptide named RDP1 (AAAAGAKAR, 785.91 Da) was identified from the extract of shelled fruits of Oryza sativa. Our results demonstrated that RDP1 (the minimum effective concentration is 10 μg/kg) could significantly reduce the serum uric acid and creatinine and alleviate hyperuricemic nephropathy in rats by intragastric administration. RDP1 inhibited xanthine oxidase, which also was verified at the animal level. Results from molecular docking indicated that RDP1 can inhibit uric acid formation by occupying the binding site of xanthine oxidase to xanthine. Besides, RDP1 showed no toxicity on rats and was stable in several temperatures, demonstrating its advantages for transportation. This research was the first discovery of antihyperuricemic peptide from the shelled fruits of O. Sativa and provided a new candidate for the development of hypouricemic drugs.

Protective effects of tuna meat oligopeptides (TMOP) supplementation on hyperuricemia and associated renal inflammation mediated by gut microbiota

“…The gut microbiota is established during the development of the host, and its composition and metabolism are closely associated with chronic metabolic syndromes. 29,30 Although various studies have shown that antihyperuricemia effects of protein hydrolysates in cell and mice models, 7,31 the underlying mechanism and the modulation effects of the protein hydrolysates on gut microbiota, remain unclear.…”

“…Small molecule phytochemicals (flavonoids, anthocyanins, alkaloids, etc) have been the focus of treatments for hyperuricemia and renal inflammation for many years, and commonly their therapeutic target is only one of the pathways involved in uric acid metabolism or inflammatory signaling regulation. 3,7,8 However, due to the difficulty in producing and storing small molecule compounds, biomacromolecules with high activity, stability, and specificity, such as active oligopeptides, have attracted increasing interest in alleviating hyperuricemia. Various novel peptides were isolated, and their dose-dependent antihyperuricemia effects and mechanisms were investigated.…”

“…Various novel peptides were isolated, and their dose-dependent antihyperuricemia effects and mechanisms were investigated. 7,9,10 Because the separation of peptides is a time-and labor-consuming process, interest in using whole food derived mixtures, instead of single components to prevent chronic metabolic syndrome has increased. 11,12 Compared with signal peptides, protein hydrolysates exert combined and better effects on regulating uric acid metabolism and alleviating renal inflammation, partly due to the complex peptide composition and potential synergistic interactions among these peptides.…”

Bioactive Compounds from Plant-Based Functional Foods: A Promising Choice for the Prevention and Management of Hyperuricemia

“…and UA excretion promoters (probenecid, benzbromarone, etc.) [26]. Although these drugs aid in reducing UA levels, many exhibit serious side effects, such as gastrointestinal reactions, skin rashes, liver and kidney dysfunction, and hepatotoxicity [27].…”

From Xanthine Oxidase Inhibition to In Vivo Hypouricemic Effect: An Integrated Overview of In Vitro and In Vivo Studies with Focus on Natural Molecules and Analogues

“…It was also demonstrated that this peptide inhibited XO in vitro and in vivo, probably by occupying the binding site to xanthine (docking studies). Furthermore, no acute toxicity in rats was observed, and authors also evidenced that RDP-1 was stable in several temperatures [105].…”